| 词条 | Cinaciguat |
| 释义 |
| Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 444574102 | IUPAC_name = 4-({(4-carboxybutyl)[2-(2- phenyl]methoxy}phenyl)ethyl]amino}methyl) benzoic acid | image = Cinaciguat_structure.svg | tradename = | pregnancy_AU = | pregnancy_US = | pregnancy_category = | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = | routes_of_administration = intravenous (?) | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion = | IUPHAR_ligand = 5168 | CAS_number_Ref = {{cascite|correct|??}} | CAS_number = 329773-35-5 | CAS_supplemental = | ATC_prefix = none | ATC_suffix = | ATC_supplemental = | ChEBI = 142433 | PubChem = 9808022 | DrugBank_Ref = {{drugbankcite|correct|drugbank}} | DrugBank = | UNII_Ref = {{fdacite|correct|FDA}} | UNII = 59K0Y58UAD | ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} | ChemSpiderID = 7983781 | StdInChI_Ref = {{stdinchicite|changed|chemspider}} | StdInChI = 1S/C36H39NO5/c38-35(39)12-6-7-24-37(26-30-19-21-33(22-20-30)36(40)41)25-23-32-10-4-5-11-34(32)42-27-31-17-15-29(16-18-31)14-13-28-8-2-1-3-9-28/h1-5,8-11,15-22H,6-7,12-14,23-27H2,(H,38,39)(H,40,41) | StdInChIKey_Ref = {{stdinchicite|changed|chemspider}} | StdInChIKey = WPYWMXNXEZFMAK-UHFFFAOYSA-N | chemical_formula = | C=36 | H=39 | N=1 | O=5 | molecular_weight = 565.697 g/mol | smiles = c4ccccc4CCc3ccc(cc3)COc1ccccc1CCN(CCCCC(O)=O)Cc2ccc(C(=O)O)cc2 }} Cinaciguat (BAY 58-2667) is an experimental drug for the treatment of acute decompensated heart failure. Mechanism of actionCinaciguat activates the soluble guanylate cyclase (sGC) which is a receptor for nitric oxide. This increases biosynthesis of cyclic GMP, resulting in vasodilation.[1] See also
References1. ^Schubert-Zsilavecz, M, Wurglics, M, Neue Arzneimittel 2009 {{Nitric oxide signaling}}{{cardiovascular-drug-stub}} 3 : Vasodilators|Benzoic acids|Phenol ethers |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。